Details

Autor(en) / Beteiligte

• Booth, Heather D.E.
• Wessely, Frank
• Connor-Robson, Natalie
• Rinaldi, Federica
• Vowles, Jane
• Browne, Cathy
• Evetts, Samuel G.
• Hu, Michele T.
• Cowley, Sally A.
• Webber, Caleb
• Wade-Martins, Richard

Titel

RNA sequencing reveals MMP2 and TGFB1 downregulation in LRRK2 G2019S Parkinson's iPSC-derived astrocytes

Ist Teil von

• Neurobiology of disease, 2019-09, Vol.129, p.56-66

Ort / Verlag

United States: Elsevier Inc

Erscheinungsjahr

2019

Quelle

MEDLINE

Beschreibungen/Notizen

• Non-neuronal cell types such as astrocytes can contribute to Parkinson's disease (PD) pathology. The G2019S mutation in leucine-rich repeat kinase 2 (LRRK2) is one of the most common known causes of familial PD. To characterize its effect on astrocytes, we developed a protocol to produce midbrain-patterned astrocytes from human induced pluripotent stem cells (iPSCs) derived from PD LRRK2 G2019S patients and healthy controls. RNA sequencing analysis revealed the downregulation of genes involved in the extracellular matrix in PD cases. In particular, transforming growth factor beta 1 (TGFB1), which has been shown to inhibit microglial inflammatory response in a rat model of PD, and matrix metallopeptidase 2 (MMP2), which has been shown to degrade α-synuclein aggregates, were found to be down-regulated in LRRK2 G2019S astrocytes. Our findings suggest that midbrain astrocytes carrying the LRRK2 G2019S mutation may have reduced neuroprotective capacity and may contribute to the development of PD pathology. •Genome-wide RNA sequencing profiling of LRRK2 G2019S iPSC-derived astrocytes.•The extracellular matrix is perturbed in LRRK2 G2019S iPSC-astrocytes.•MMP2 and TGFB1 are down-regulated in the presence of the LRRK2 G2019S mutation.•Reduced neuroprotective potential of astrocytes may contribute to PD pathology.